DNA repair inhibitors sensitize cells differently to high and low LET radiation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 12 2021
Historique:
received: 15 12 2020
accepted: 15 11 2021
entrez: 2 12 2021
pubmed: 3 12 2021
medline: 27 1 2022
Statut: epublish

Résumé

The aim of this study was to investigate effects of high LET α-radiation in combination with inhibitors of DDR (DNA-PK and ATM) and to compare the effect with the radiosensitizing effect of low LET X-ray radiation. The various cell lines were irradiated with α-radiation and with X-ray. Clonogenic survival, the formation of micronuclei and cell cycle distribution were studied after combining of radiation with DDR inhibitors. The inhibitors sensitized different cancer cell lines to radiation. DNA-PKi affected survival rates in combination with α-radiation in selected cell lines. The sensitization enhancement ratios were in the range of 1.6-1.85 in cancer cells. ATMi sensitized H460 cells and significantly increased the micronucleus frequency for both radiation qualities. ATMi in combination with α-radiation reduced survival of HEK293. A significantly elicited cell cycle arrest in G

Identifiants

pubmed: 34853427
doi: 10.1038/s41598-021-02719-9
pii: 10.1038/s41598-021-02719-9
pmc: PMC8636489
doi:

Substances chimiques

Histones 0
Radiation-Sensitizing Agents 0
ATM protein, human EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins EC 2.7.11.1
DNA-Activated Protein Kinase EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23257

Informations de copyright

© 2021. The Author(s).

Références

N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Int J Oncol. 2014 Nov;45(5):1813-9
pubmed: 25174607
PLoS One. 2013 Aug 27;8(8):e72641
pubmed: 24013362
Biochem Biophys Res Commun. 2017 Apr 29;486(2):307-313
pubmed: 28300555
Semin Radiat Oncol. 2007 Apr;17(2):121-30
pubmed: 17395042
Mol Cell. 2009 Mar 13;33(5):547-58
pubmed: 19285939
Sci Rep. 2019 Dec 6;9(1):18489
pubmed: 31811257
Mol Cell Biol. 1999 May;19(5):3877-84
pubmed: 10207111
Front Oncol. 2018 Jul 13;8:245
pubmed: 30057890
Nat Rev Cancer. 2009 Feb;9(2):134-42
pubmed: 19148183
Sci Adv. 2018 Jun 20;4(6):eaat1719
pubmed: 29938225
Cancer Sci. 2016 Sep;107(9):1250-5
pubmed: 27341700
Semin Cancer Biol. 2015 Dec;35 Suppl:S5-S24
pubmed: 25869442
J Nucl Med. 2020 May;61(5):683-688
pubmed: 31601699
Nucleic Acids Res. 2010 Jun;38(10):3245-51
pubmed: 20150414
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
Nat Rev Cancer. 2006 Sep;6(9):702-13
pubmed: 16929324
Cancers (Basel). 2019 Dec 13;11(12):
pubmed: 31847107
Mol Cancer Ther. 2020 May;19(5):1091-1101
pubmed: 32220971
Cancer Res. 2004 Dec 15;64(24):9152-9
pubmed: 15604286
Radiat Environ Biophys. 2012 Aug;51(3):283-93
pubmed: 22526916
Int J Radiat Biol. 2003 Aug;79(8):611-21
pubmed: 14555344
Breast Cancer Res Treat. 2000 Aug;62(3):223-35
pubmed: 11072787
Radiat Res. 2014 Sep;182(3):338-44
pubmed: 25117625
Radiat Res. 2010 Jan;173(1):27-39
pubmed: 20041757
Int J Radiat Biol. 1989 Sep;56(3):287-92
pubmed: 2570814
Radiat Oncol. 2017 Dec 29;12(1):208
pubmed: 29287602
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Acta Oncol. 2005;44(1):13-22
pubmed: 15848902
Radiat Res. 2015 Mar;183(3):345-56
pubmed: 25738894
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
Mol Cell. 2004 Dec 3;16(5):715-24
pubmed: 15574327
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Radiat Res. 2006 Jan;165(1):59-67
pubmed: 16392963

Auteurs

Kristina Bannik (K)

Pharmaceuticals Division, Bayer AG, Berlin, Germany.
, Berlin, Germany.

Balázs Madas (B)

Centre for Energy Research, Budapest, Hungary.

Sabrina Jarke (S)

Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Nuvisan-ICB GmbH, Berlin, Germany.

Andreas Sutter (A)

Pharmaceuticals Division, Bayer AG, Berlin, Germany.

Gerhard Siemeister (G)

Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Nuvisan-ICB GmbH, Berlin, Germany.

Christoph Schatz (C)

Pharmaceuticals Division, Bayer AG, Berlin, Germany.

Dominik Mumberg (D)

Pharmaceuticals Division, Bayer AG, Berlin, Germany.

Sabine Zitzmann-Kolbe (S)

Pharmaceuticals Division, Bayer AG, Berlin, Germany. sabine.zitzmann-kolbe@bayer.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH